Scientific Industries Reports Improved Net Loss of $1.22 Million for Fiscal Year 2025

Scientific Industries, Inc. reported a net loss of $1.22 million for the fiscal year ending December 31, 2025, a significant improvement from a net loss of $6.45 million in the previous year. The company’s net revenues increased by 5.4% to $5.05 million, up from $4.80 million in 2024. This growth was primarily driven by increased sales from the Benchtop Laboratory Equipment segment, particularly the Torbal® division, which offset a decline in revenues from the Bioprocessing Systems segment. The gross profit margin decreased to 25.8% from 41.8% in the prior year, largely due to inventory write-offs in the Bioprocessing segment.

A key strategic development for Scientific Industries was the sale of its Genie product line on August 7, 2025, which resulted in a gain of $5.26 million. This divestiture allowed the company to streamline its operations and focus on its remaining product lines, including the Torbal® weighing products and the Bioprocessing Systems. The company continues to invest in product development, particularly in its Bioprocessing Systems operations, which are expected to generate meaningful revenues in the future. Research and development expenses decreased to $2.49 million from $2.90 million in the previous year, reflecting cost-saving measures.

Operationally, the company employed 55 individuals as of March 31, 2026, with 21 in the Benchtop Laboratory Equipment operations and 34 in the Bioprocessing Systems operations. The company’s sales strategy includes a direct sales force and a network of distributors, particularly for its Bioprocessing Systems products, which are marketed through various channels including trade shows and online campaigns. The company’s international sales accounted for approximately 17% of total revenues, primarily from customers in Asia and Europe.

Looking ahead, Scientific Industries anticipates continued challenges as it seeks to grow its Bioprocessing Systems segment, which is still in its early stages. The company has acknowledged the need for additional funding to support its product development and commercialization efforts. Management believes that the cash generated from the recent sale of the Genie division, along with other incoming cash related to post-sale agreements, will be sufficient to fund operations for at least one year. However, the company remains cautious about its ability to achieve profitability in the near term, given its accumulated deficit of $35.15 million as of December 31, 2025.